Bioeast Biotech
Latest round
- Series A
Last raised
- May 2022
Total raised
- $40M
Investors
- 5
About Bioeast Biotech
Based in Hangzhou, China and established in 2018, Bioeast Biotech is a pharmaceutical raw material supplier dedicated to providing IVD core raw materials and overall solutions. In has a subsidiary in Hangzhou. The company acquired ISO 13485 Quality Management System Certification. In July 2023, it was awarded the title of National Specialized and New Small Giant Enterprise. The company mainly provides core raw materials and overall solutions. It provides core raw materials such as antigens, antibodies, enzymes, quality control products, nano-microspheres, etc. Bioeast also provides nanometre microspheres, immunodiagnostics, purification media, and molecular products. The immunodiagnostics include antigens and antibodies, enzymes and proteins, and pet diagnosis. The molecular products include nucleic acid purification series, PCR (Polymerase Chain Reaction) series, qPCR (Quantitative PCR) series, and reverse transcription series. The company also provides IVD companies with comprehensive solutions for POCT (Point-of-Care Testing), immunoturbidimetry, chemiluminescence and other products. The company generates revenue by providing core raw materials and overall solutions such as nanometre microspheres, immunodiagnostics, purification media, and molecular products.
Who invested in Bioeast Biotech
5 investors across 3 rounds
See all investors in Bioeast Biotech
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Bioeast Biotech
Who invested in Bioeast Biotech?
Bioeast Biotech has 5 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Bioeast Biotech raised?
Bioeast Biotech has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Bioeast Biotech last raise money?
Bioeast Biotech's most recent round on record is a Series A, in May 2022.
What does Bioeast Biotech do?
Based in Hangzhou, China and established in 2018, Bioeast Biotech is a pharmaceutical raw material supplier dedicated to providing IVD core raw materials and overall solutions.
Where is Bioeast Biotech headquartered?
Bioeast Biotech is headquartered in Hangzhou, China.
Which VCs invest in companies like Bioeast Biotech?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Bioeast Biotech's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Bioeast Biotech? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.